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ABSTRACT 
 
Background and aim 
Cardiovascular complications are the first cause of mortality and morbidity in type 2 diabetic 
patients. Among antidiabetic drugs, those who have shown cardiovascular benefits have ancillary 
activities that simultaneously control several risk factors. In the PROACTIVE trial, pioglitazone 
determined a 16% reduction of death for all causes, non-fatal myocardial infarction, non-fatal 
stroke, compared to placebo. The aim of the study is to investigate the effects of 5 years treatment 
with pioglitazone/metformin compared to 5 years treatment with glimepiride/metformin on diabetic 
dyslipidemia, both quantitatively and qualitatively, and on glyco-oxidation processes.   
Methods 
96 diabetic patients, treated with metformin (2g/day) for at least 2 months, were randomized to 
treatment with pioglitazone or glimepiride. Patients were followed for 5 years: body mass index 
(BMI), waist circumference (CV), blood pressure, HbA1c; total cholesterol (CT), high density 
lipoproteins (HDL), low density lipoproteins (LDL), triglycerides (TG), advanced glycation end 
products (AGE), oxidized LDL (oxLDL) were determined at baseline and after 5 years of treatment.  
Results 
Treatment with pioglitazone resulted in significant increase in HDL (47.1±11.7 vs 51.3±15.7 mg/dl; 
p=0.02), non-significant reduction in CT, LDL and TG. Glimepiride treatment resulted in a 
significant reduction in HDL (48.6±14.1 vs 45.8±12.7 mg/dl; p=0.03), a non-significant reduction 
in CT, LDL and TG. Only the variation of HDL and oxLDL were significantly different between 
the two groups (ΔHDLPioglitazone= +4.2±10.5 mg/dl vs ΔHDLGlimepride= -2.9±7.7 mg/dl; p=0.002); 
(ΔoxLDLPioglitazone= -2.1±9.8 U/l vs ΔoxLDLGlimepride= +3.6±11.4 U/l; p=0.01). 
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AGEs reduction, significant for both treatments, is not significantly different between the two 
groups. HbA1c reduction was significant only in patients treated with glimepiride (7.7±0.4 vs 
7.1±0.8 %; p <0001) and was not correlated with AGEs variation (r=1.22; p=0.59). 
Conclusions 
Long-term treatment with pioglitazone significantly improves lipid profile of type 2 diabetic 
patients, increasing HDL levels and reducing oxLDL levels. In addition, it reduces AGEs 
formations. The inhibition of glyco-oxidative processes is one of the mechanisms that may explain 
the drug ability to prevent cardiovascular events. 
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INTRODUCTION 
Cardiovascular disease is the most common cause of morbidity and mortality in patients with 
diabetes (1). It is known that diabetes, obesity, hypertension, dyslipidemia and smoking habit, 
account for over 80% of the risk of myocardial infarction (2). On the other hand it is known that 
many times diabetes isn’t an isolated disease, but it is within the framework of metabolic syndrome: 
the simultaneous presence of obesity, hypertension, dyslipidemia, insulin resistance and 
hyperglycemia (3). Thus diabetic patients have a higher risk of atherosclerosis than the general 
population which lead to diffuse vascular damage and multi-organ dysfunction. In the long term, 
diabetic patients risk both micro- and macrovascular complications (4).  
The findings of the Diabetes Control and Complications Trial (DCCT) and the UK Prospective 
Diabetes Study (UKPDS) have confirmed that hyperglycemic injury is the primary causal factor 
behind vascular damage, specially microvascular damage (5, 6).  
Hyperglycemia promotes vascular damage through at least five main mechanisms: an increased flux 
of glucose and other sugars through the polyol pathway; an increased intracellular advanced 
glycation end products (AGE) formation; interaction between AGEs and their receptors (termed 
RAGEs) leading to intracellular signaling, which disrupts cell function (7); a persistent activation of 
protein kinase C (PKC) isoforms (8); and an increased hexosamine pathway activity (9). Among all, 
advanced AGE excess is one of the most important mechanism.  
Another important factor that promotes vascular damage in terms of atherosclerosis in diabetic 
patients is the quantitative and qualitative alterations of the lipid profile. Below we analyze these 
factors in detail.  
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ADVANCED GLYCATION END PRODUCTS AND CARDIOVASCULAR 
COMPLICATIONS 
The most important process responsible for AGE accumulation in diabetic patients is the non-
enzymatic glycation reaction, or Maillard reaction. This can be globally seen as a three-step 
process, the final stage of which comprises a complex series of oxidation, dehydration and 
cyclization reactions, which give rise to so-called endogenous AGEs, i.e. thermodynamically 
unstable compounds that typically accumulate on proteins with a long half-life, though they have 
recently been shown to form on proteins with a short half-life too, such as plasma proteins, 
lipoproteins, and intracellular proteins (10). Much attention has recently been paid to the so-called 
exogenous AGEs, harmful products of "browning" (or the Maillard reaction) in various foods. 
Together with endogenous AGEs, these compounds form the majority of glycation-free adducts, the 
greater proportion of circulating AGEs in diabetic and non-diabetic subjects. Among the various 
food processing methods, heating, sterilizing, and microwaves contribute to the generation of 
exogenous AGEs, all of which tend to accelerate the nonenzymatic addition of non-reducing sugars 
to free NH2 groups of proteins and lipids (11). 
The main mechanisms behind the tissue damage caused by AGEs are intracellular glycation, cross-
link formation and interaction with RAGEs. The intracellular accumulation of AGEs alters 
cytoplasmic and nuclear factors, including the proteins involved in regulating gene transcription 
(12). Another important mechanism is the formation of stable abnormal cross-links on collagen, 
which causes chemical and physical changes in the collagen’s structure and consequent functional 
changes typical of chronic diabetic complications, such as basement membrane thickening with a 
resistance to proteolytic digestion (13) and arterial stiffening. Finally, the AGE-RAGE interaction 
leads to cellular signaling, including nuclear factor-kB (NF-kB) activation, increased cytokine and 
adhesion molecule expression, induction of oxidative stress (14). 
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An excessive AGE formation has been implicated in the newly disclosed biochemical pathways 
involved in the microvascular pathobiology of type 2 diabetes, confirming its central role in the 
progression of microvascular complications (diabetic neuropathy, retinopathy and nephropathy). 
Moreover, AGEs play an important part in the development of cardiovascular complications in 
patients with type 2 diabetes. From the first observations of high AGE levels in atherosclerotic 
coronary plaque in selected type 2 diabetic patients (15) to Kiuchi et al.’s demonstration that serum 
AGE concentrations increase consistently with the severity of coronary atherosclerosis in type 2 
diabetic patients with obstructive coronary artery disease (16), the hypothesis that AGE 
concentrations may be a risk marker in type 2 diabetic patients with coronary atherosclerosis has 
taken shape and has been put to the test. The results of many studies show a strong correlation 
between glycoxidation markers and the onset of complications, in terms of cardiovascular events or 
vascular damage in type 2 diabetes (17-19).  
RAGE-ligand axis has an important player in modulating several steps of atherogenesis in fact 
AGEs induced oxidative stress through interaction with RAGEs. The binding of AGEs to RAGE of 
monocytes/macrophages induces the production of cytokines (interleukin 1B, TNF-alpha, IGF-1, 
PDGF) and growth factors, with a consequent increase in the synthesis of type IV collagen, a 
greater proliferation of vessel smooth muscle cells, and a stimulation of macrophage chemotaxis. In 
addition, through a mechanism of oxidative stress, AGE-RAGE binding on endothelial cells 
induces the transcription factor NF-kB, which in turn increases the expression of the vascular 
cellular adhesion molecule (VCAM-1). The resulting VCAM-1 overexpression increases the 
adhesivity of monocytes to endothelial cells, and vascular permeability, speeding up the trans-
endothelial passage of AGE-modified proteins. At last AGE-RAGE binding has been shown to 
specifically reduce endothelial nititc oxide (NO) activity and NO production through a series of 
complex interactions with multiple enzymes (20). The role of AGE-RAGE binding is therefore both 
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to kick off the atherosclerotic process, both to maintain the inflammatory state in the progression of 
atherosclerotic plaque. 
It is known that microvascular changes occurring in the first stage of diabetic disease could be 
reversible if the patient’s hyperglycemia is corrected promptly; if it is not, the resulting 
macrovascular changes are irreversible (21).  
It could be hypothesized that in the early years of the disease there is a linear relationship between 
hyperglycemia, increased oxidative stress and excessive AGE formation, with all three factors 
linked by a causal association; later on, persistent respiratory chain protein glycation and DNA 
damage in the mitochondria generate a hyperglycemia-independent vicious cycle (22), in which 
oxidative stress is self-supporting and AGEs "feed" this process (Figure 1).  
The main downstream effects of this physiopathological scenario include changes in the 
composition and structure of the extracellular matrix, mediated by inflammatory processes induced 
by receptor binding of AGEs or oxidative stress. Subsequent fibrosis and the extension of the 
extracellular structures interfere with capillary blood flow, reducing capillary density in particular 
(21). These structural changes reduce the flow reserve and this can directly affect upstream arteries, 
causing endothelial dysfunction (overtime) and then atherosclerosis and cardiovascular disease. 
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Figure 1. Schematic overview of the different etiological contributions of hyperglycemia, AGEs and 
oxidative stress in different phases of diabetes mellitus (23). 
 
DIABETIC DYSLIPIDEMIA AND CARDIOVASCULAR COMPLICATIONS 
In type 2 diabetic patients the alterations of the lipid profile play an important role in the 
etiopathogenesis and progression of atherosclerosis. These alterations are both quantitative and 
qualitative: increased triglyceride (TG) levels; qualitative changes in low density lipoproteins 
(LDL); both quantitative and qualitative alterations of high density lipoproteins (HDL) (24). 
In diabetic patients, TG levels are significantly higher than in the non-diabetic population and 
represent an independent risk factor for cardiovascular complications (25). Insulin resistance, 
typical of type 2 diabetic patients, leads to an increase in lipolysis and the release of free fatty acids 
(FFA) from adipose tissue and a lower uptake of these by skeletal muscle. Therefore the liver 
concentrations of FFA and the synthesis of very low density lipoprotein (VLDL), lipoproteins 
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whose main function is the transport of triglycerides, increase (26, 27). The result of these 
mechanisms is the increase of TG levels.  
As regards LDL cholesterol, in the diabetic patients their levels are normal or only slightly 
increased, although it is formed by the catabolism of the VLDL which are significantly increased, 
because the catabolism of the VLDL is reduced (28). The alterations of LDL cholesterol are 
qualitative, alterations in density and dimensions. In fact diabetic patients have higher levels of 
small and dense LDL than non diabetic subjects.  
This alteration is due to the presence of high levels of circulating VLDL and the consequent 
activation of the cholesteryl ester transfer protein (CETP), which transfers triglycerides from VLDL 
to HDL and LDL, in exchange for cholesterol esters. the ester content of LDL cholesterol decreases 
and increases the triglyceride content, which makes it more susceptible to lipolytic action of hepatic 
lipase: the result is the formation of smaller and denser LDL (29). Small and dense LDLs have 
greater atherogenic potential, mainly because such lipoproteins are substrates of glycation and 
oxidation processes, as well as having facilitated penetration through the endothelium and favoring 
foam cell formation (30, 31). In fact, oxidized LDLs (oxLDL) have less affinity for LDL receptor 
and have a preferential internalization pathway in endothelial macrophages (32). Moreover, the 
oxidized LDL induces the synthesis of some endothelial cytokines, in particular the intercellular 
adhesion molecules 1 (ICAM-1), and macrophages (TNFα and IL-1), with a pro-inflammatory 
effect that favors atherosclerosis (29, 32). 
At last, diabetic patients have quantitative and qualitative alterations of HDL cholesterol. HDL 
levels in diabetic patients are lower than non diabetic patients (25). In fact, the increase of VLDL 
determines a greater activity of the CETP enzyme, which removes cholesterol esters from HDL, 
enriching them in triglycerides and making them more susceptible to catabolism by the hepatic 
lipase (24). These mechanisms lead to a quantitative reduction of HDL levels in diabetic patients; 
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however, it is now evident that cardiovascular risk is significantly associated with qualitative as 
well as quantitative alteration.  
The main qualitative alterations of HDL are their glycation and oxidation; both of these processes 
determine a reduction in the ability of reverse cholesterol transport. A recent published study 
showed that patients with type 2 diabetes and patients with early myocardial infarction have 
elevated levels of oxidized ApoA1 (oxApoA1) regardless of HDL cholesterol levels (33). The 
oxidation of ApoA1 reduces the antioxidant potential of HDL and alters its ability to bond with 
ABCA1 transporters, thus compromising the reverse transport of cholesterol (34). 
 
ANTIHYPERGLYCAEMIC DRUGS AND CARDIOVASCULAR COMPLICATIONS: 
THIAZOLIDINEDIONES AND SULPHONYLUREAS 
It is known that hyperglycemia is one of the factors that independently predicts the risk of 
cardiovascular events and that it is primary achieve a good glycaemic control early to prevent 
cardiovascular events. The results of UKPDS showed that good glycaemic control established at the 
time of diagnosis can reduce the incidence of cardiovascular events (35). However, it is necessary 
to analyze how to obtain good glycaemic control because the ACCORD, ADVANCE and VADT 
studies have suggest that it is essential to choose the right treatment for the type of patient to be 
treated to obtain a reduction in cardiovascular risk (36-38).  
In literature there are several studies that have investigate the effect of different antidiabetic drugs 
on cardiovascular risk. In fact after the withdrawal of rosiglitazone, the Food and Drug 
Administration (FDA) has established that for the approval of new antidiabetic drugs it is necessary 
to ensure their cardiovascular safety by performing randomized placebo-controlled trials.  
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In particular, the results of the studies suggest that pioglitazone could reduce the cardiovascular risk 
of type 2 diabetic patients while sulphonylureas (as glimepiride) seem to have adverse 
cardiovascular effects.  
Pioglitazone is a peroxisome proliferator-activated receptor γ (PPARγ) agonist, a cellular 
transcription factor involved in the regulation of glucose and lipid homeostasis. The hypoglycaemic 
effect is due to an increase in insulin sensitivity of the liver, skeletal muscle, adipose tissue (39).  
Pioglitazone has a demonstrated efficacy in lowering TG and raising HDL-C levels, superior to that 
of metformin or sulfonylurea, in type 2 diabetic patients (40). Moreover, despite its neutral effect on 
LDL cholesterol, treatment with pioglitazone reduces the number of small dense LDL (41). These 
quantitative effects on the lipid profile were confirmed by long-term studies (42), regardless of an 
individual’s glycemic control or any concomitant use of statins. 
Pioglitazone has also been associated with an anti-inflammatory and antioxidant activity in patients 
with type 2 diabetes (43), particularly as regards AGE (44). 
As summarized in Figure 2, pioglitazone has effects on both lipoproteins and glyco-oxidation 
processes and therefore a protective cardiovascular effect of the drug can be hypothesized. 
 
Figure 2. Effects of pioglitazone on lipoproteins and glyco-oxidation processes. 
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The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE), a 
prospective, randomised controlled trial in 5238 patients with type 2 diabetes who had evidence of 
macrovascular disease, investigators studied the effect of pioglitazone on cardiovascular risk (42). 
In particular the primary outcome was: all-cause mortality, non-fatal myocardial infarction 
(including silent myocardial infarction), stroke, acute coronary syndrome, endovascular or surgical 
intervention on the coronary or leg arteries, or amputation above the ankle. The main secondary 
endpoint was the composite of all-cause mortality, non-fatal myocardial infarction, and stroke. The 
results showed that treatment with pioglitazone reduced significantly the secondary endpoint by 
16%.  
On the other hand, sulphonylureas stimulate insulin secretion from pancreatic b-cells by binding to 
the sulfonylurea receptor 1, which is part of the Kir6.2 adenosine triphosphate-sensitive potassium 
channel.  
In literature there several concerns about the cardiovascular safety of this drugs. Kir6.2 adenosin 
triphosphate-sensitive potassium channel is also expressed in smooth muscle cells and 
cardiomyocytes and several authors have postulated that the increased CV mortality induced by 
sulphonylureas could be the result of an impaired vasodilatory response during acute myocardial 
ischemia. Although several hypotheses linking sulphonylureas to adverse cardiovascular effects 
exist, none provide conclusive evidence (45). Moreover in literature there are many conflicting 
data: some studies showed a negative effect on cardiovascular risk and others showed a neutral 
effect. It is to underline that the majority of these studies were not specifically designed to assess 
the effect of sulphonylureas on adverse cardiovascular event risk.  
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AIM OF THE STUDY 
 
The aim of this study was to investigate the long-term effects of 5 years-treatment with pioglitazone 
plus metformin compared to treatment with glimepiride plus metformin on glycation processes and 
on lipid profile (quantitative and qualitative alterations) in type 2 diabetic patients.  
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MATERIALS AND METHODS 
 
Subjects 
The study was conducted within the framework of the TOSCA.IT trial (Thiazolidinediones Or 
Sulphonylureas and Cardiovascular Accidents. Intervention Trial; NCT00700856, 
ClinicalTrials.gov), a randomized clinical trial (RCT) designed to assess the cardiovascular effects 
of two different hypoglycemic drug regimens (sulfonylurea or pioglitazone) (46). 
 The protocol was approved by the Ethics Review Committee/Institutional Review Board of the 
Coordinating Center and each participating center. The study was conducted in accordance with the 
Declaration of Helsinki and the Good Clinical Practice guidelines. Written informed consent was 
obtained from participants before beginning any protocol-specific procedure and participants were 
told that they had the right to withdraw from the study at any time. 
The inclusion criteria were: 
- Type 2 diabetes of at least 2 years duration 
- Males and females, age 50-75 years 
- BMI 20-45 Kg/m2 
- Stable treatment for the last two months with metformin in monotherapy at 2 g/day 
- HbA1c ≥ 7.0% and ≤ 9.0% 
The exclusion criteria were: 
- Type 1 diabetes 
- Previous treatment with TDZs within the last six months 
- Contraindication/intolerance to metformin or SUs or TZDs 
- Documented coronary or cerebrovascular events within the previous 3 months 
- Serum creatinine > 1.5 mg/dl 
- History of congestive heart failure, NYHA class I or higher 
- Chronic use of glucocorticoids 
14 
 
- Ischemic ulcer or gangrene of lower extremities 
- Liver cirrhosis or severe hepatic dysfunction (ALT > 2.5 times the upper normal limit) 
-  Pregnancy or breast feeding 
- Cancer, substance abuse, or any health problem that may interfere with the compliance to 
the study protocol or limit life expectancy 
Eligible patients are randomized to one of two treatments: metformin plus sulfonylurea (glimepiride 
2 mg) or metformin plus pioglitazone (15 mg). The treatment allocation schedule was computer-
generated in blocks and stratified by clinical status and previous cardiovascular events. The 
participating centers were masked to the randomization sequences, which were generated at the 
Epidemiology Unit. 
Data reported in this study were collected from the 96 patients recruited for the TOSCA.IT trial at 
the Diabetology and Dietetics Unit in Padua, Italy. A blood test was performed at the time of their 
randomization and after 5 years, in accordance with the RCT procedures, to obtain biochemical 
parameters of glyco-oxidation and lipid profiles. 
 
Methods 
 
At baseline and after 5 years of treatment in all patients we assessed: weight, height, body mass 
index (BMI), waist, systolic and diastolic blood pressure. 
 
Basic blood chemistry parameters and markers of glyco-oxidation 
HbA1c was measured by high-performance liquid chromatography (HPLC, Menarini Akray 
ADAM A1c HA-8180v), in line with IFCC standards (International Federation of Clinical 
Chemistry) (47). 
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Total cholesterol, LDL-C and HDL-C were measured using an enzymatic colorimetric method 
(COBAS 8000; Roche, Milan) (48), as were TG (GPO-PAP colorimetric enzyme tests; Roche 
Diagnostic System) (49). 
An ELISA method was used to assay oxLDL, with 2 monoclonal antibodies specific for antigens on 
apolipoprotein B (Mercodia Oxidized LDL ELISA, Uppsala, Sweden), obtaining an intra-assay 
coefficient of variation <5% and an interassay coefficient of variation <10% (50). 
Serum AGE  were estimated by means of an ELISA assay, using a polyclonal antibody (51). 
 
Statistical analysis 
Continuous values are given as means ± standard deviations (SD). The comparison between 
continuous variables at baseline and after one year of treatment was calculated as the pre-post 
difference (HbA1c, TC, HDL, LDL, TG, oxLDL, AGE). Negative delta values (Δ) therefore 
indicate the actual decrease in the parameter depending on the treatment administered. The 
statistical significance of these differences (pre-post) in each treatment group was analyzed using 
Student’s t-test for paired data, after checking the normality of the distribution of the parameters 
according to the skewness and kurtosis parameters, and after normalizing differences at the 
baseline. 
The two treatment groups were compared with Student’s t-test for unpaired data. All differences 
were considered statistically significant with a p-value <0.05. 
 For each parameter (SBP, DBP, BMI, HbA1c, TC, HDL, LDL, TG, oxLDL, AGE), an analysis of 
variance (ANOVA) between the two groups of patients (pioglitazone vs glimepiride) was 
performed at the baseline and after 5 years of treatment. For the nominal variables, the differences 
between the two groups (pioglitazone vs. glimepiride) were estimated with Fisher’s exact test. 
To prevent any interference of anthropometric and clinical characteristics in the associations 
between variables, a stepwise forward multiple regression analysis was performed, where 
appropriate.  
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RESULTS 
 
The data for all 96 patients assessed at the baseline and after 5 years were considered in the 
statistical analysis. There were no dropouts from the study. 47 patients were treated with metformin 
plus pioglitazone and 49 patients were treated with metformin plus glimepiride. 
The patients randomly assigned to the two treatments were similar as regards the following 
variables at the baseline (Table 1): male/female ratio, duration of diabetes, smoking habits, blood 
pressure, BMI and waist circumference (WC). The two groups were also comparable in terms of 
glycemic control, lipid profiles, markers of lipid oxidation and glyco-oxidation, and there were no 
differences in their treatment with statins. 
 
Table I. Baseline anthropometric and clinical parameters of the two treatment groups. Continuous 
data are expressed as mean ± SD. Differences between groups were assessed with Student’s t-test 
for continuous variables, and Fisher’s exact test for nominal variables. 
   Pioglitazone (n=47) Glimepiride (n= 49) 
Disease duration (y) 8.0±5.0 8.0±4.7 
Gender (male/female)  28/19 26/23 
Statin (yes/no) 25/22 27/20 
SBP (mmHg) 131.1±10.7 135.1±13.7 
DBP (mmHg) 80.5±7.0 80.8±7.1 
BMI (kg/m
2
)  29.3±4.0 29.6±4.2 
Waist (cm)  101.7±11.2 99.7±10.2 
HbA1c (%)  7.6±0.4 7.7±0.4 
TC (mg/dl)  174.9±31.7 182.5±36.7 
HDL (mg/dl)  47.1±11.7 48.6±14.1 
LDL (mg/dl)  106.8±27.0 110.1±31.4 
TG (mg/dl)  132.0±53.6 149.9±70.2 
oxLDL (U/l)  40.1±7.9 40.9±8.9 
AGE (ug/ml)  27.2±13.3 25.9±11.4 
 
Table 2 shows the anthropometric and clinical parameters after 5 years of treatment. The two 
groups were similar for all the parameters evaluated except for oxLDL: values in the group treated 
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with pioglitazone were significant lower than the group treated with glimepiride (38.0±9.6 vs 
44.1±12.5 U/l; p=0.04). 
 
Table 2. Anthropometric and clinical parameters of the two treatment groups after 5 years of 
treatment. Continuous data are expressed as mean ± SD. Differences between groups were assessed 
with Student’s t-test for continuous variables, and Fisher’s exact test for nominal variables. *p<0.05 
   Pioglitazone (n=47) Glimepiride (n= 49) 
Statin (yes/no) 31/16 37/12 
SBP (mmHg) 135.1±12.6 138.9±10.4 
DBP (mmHg) 80.9±6.6 80.7±7.1 
BMI (kg/m
2
)  30.4±4.6 30.1±4.3 
Waist (cm)  102.3±11.9 101.2±9.6 
HbA1c (%)  7.4±0.9 7.1±0.8 
TC (mg/dl)  170.7±29.2 173.5±34.5 
HDL (mg/dl)  51.3±15.7 45.8±12.7 
LDL (mg/dl)  100.9±22.9 104.2±30.7 
TG (mg/dl)  116.7±39.0 137.7±58.4 
oxLDL (U/l)  38.0±9.6* 44.1±12.5 
AGE (ug/ml)  8.2±7.1 9.2±5.9 
 
Than we evaluated the comparison of the anthropometric and clinical parameters at baseline and 
after 5 years of treatment with pioglitazone plus metformin (Table 3). In particular there were: a 
significant increase of BMI (29.3 ± 4.0 vs 30.4 ± 4.6 kg/m
2
; p<0.001); a significant increase of 
HDL (47.1 ± 11.7 vs 51.3 ± 15.7 mg/dl, p = 0.02); a significant reduction of AGEs (28.1±13.4 vs 
7.5±5.6 ug ml; p <0.001); a reduction, even not significant, of oxLDL, TC, LDL, TG and HbA1c. 
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Table 3. Anthropometric and clinical parameters of the group treated with pioglitazone: comparison 
between baseline and after 5 years. Data are expressed as mean ± SD. Differences between groups 
were assessed with Student’s t-test.  *p<0.05; ** p<0.001 
   Baseline After 5 years 
Statin (yes/no) 25/22 31/16 
SBP (mmHg) 131.1/±10.7 135.1±12.6 
DBP (mmHg) 80.5±7.0 80.9±6.6 
BMI (kg/m
2
)  29.3±4.0 30.4±4.6** 
Waist (cm)  101.7±11.2 102.3±11.9** 
HbA1c (%)  7.6±0.4 7.4±0.9 
TC (mg/dl)  174.9±31.7 170.7±29.2 
HDL (mg/dl)  47.1±11.7 51.3±15.7* 
LDL (mg/dl)  106.8±27.0 100.9±22.9 
TG (mg/dl)  132.0±53.6 116.7±39.0 
oxLDL (U/l)  40.1±7.9 38.0±9.6 
AGE (ug/ml)  27.2±13.3 9.2±5.9** 
 
As regards the group treated with glimepiride plus metformin, after 5 years of treatment we 
observed, as shown in Table 4: a significant reduction of HbA1c (7.7±0.4 vs. 7.1±0.8%; p<0.001), a 
significant reduction of HDL (48.6±14.1 vs 45.8±12.7 mg/dl; p= 0.03), a significant reduction of 
AGEs (25.9±11.4 vs 9.2±5.9 ug/ml; p <0.001). In this group there was also a significant increase in 
statin use that was not observed in the group treated with pioglitazone. 
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Table 4. Anthropometric and clinical parameters of the group treated with glimepiride: comparison 
between baseline and after 5 years. Data are expressed as mean ± SD. Differences between groups 
were assessed with Student’s t-test.  *p<0.05; ** p<0.001 
   Baseline After 5 years 
Statin (yes/no) 27/20 37/12* 
SBP (mmHg) 135.1±13.7 138.9±10.4 
DBP (mmHg) 80.8±7.1 80.7±7.1 
BMI (kg/m
2
)  29.6±4.2 30.1±4.3 
Waist (cm)  99.7±10.2 101.2±9.6 
HbA1c (%)  7.7±0.4 7.1±0.8** 
TC (mg/dl)  182.5±36.7 173.5±34.5 
HDL (mg/dl)  48.6±14.1 45.8±12.7* 
LDL (mg/dl)  110.1±31.4 104.2±30.7 
TG (mg/dl)  149.9±70.2 137.7±58.4 
oxLDL (U/l)  40.9±8.9 44.1±12.5 
AGE (ug/ml)  25.9±11.4 9.2±5.9** 
 
To verify the possible difference in terms of effectiveness of the two different treatments 
(pioglitazone vs glimepiride) we compared the variations (after-minus-before treatment) of the 
parameters evaluated. Both treatments led to a reduction in HbA1c values with no significant 
difference between groups (Δgli=-0.6±0.8% vs Δpio=-0.3±0.9%; p=0.06).  
Only patients treated with pioglitazone experienced an increase in HDL-C while patients treated 
with glimperide experience a reduction with a significant difference between the two groups 
(ΔHDLpio=+4.2± 10.5 mg/dl vs ΔHDLgli=-2.9±7.7 mg/dl; p=0.002) (Figure 3). No statistically 
significant differences were observed in terms of in CT, TG and LDL-C.  
As regards oxLDL levels, a significant difference was observed between the two groups: treatment 
with pioglitazone shows a tendency to reduce oxidation of LDL, while treatment with glimepiride 
tends to increase them (ΔoxLDLpio = -2.1±9.8 U/ l vs ΔoxLDLgli = +3.6 11.4 U/ l, p between the 
two groups= 0.01). Finally, the two treatment leads a significant reduction of AGEs levels, with no 
significant difference between the two groups (Figure 3). 
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Figure 3. Comparison of the variations (after-minus-before treatment) between pioglitazone and 
glimepiride treatments of HDL, oxLDL and AGE. 
To analyze better the reduction of AGEs obtained in both groups, a linear regression analysis was 
run between ΔHbA1c and ΔAGE and no significant association was found (r=1.22; p=0.59). Then a 
stepwise forward multivariate regression analysis was run with ΔAGE as the independent variable, 
while the other parameters (sex, duration of disease, use of statins, ΔHDL-C, ΔBMI, ΔHbA1c, 
ΔAGE) were included as covariates. This analysis confirmed no significant association between 
ΔHbA1c and ΔAGE (r = 1.70; p = 0.46) and showed a slight association, that failed to reach  
statistical significance, between ΔAGE and use of statin (r=8.69; p=0.07). 
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DISCUSSION 
This study showed that long-term treatment with pioglitazone in addition to metformin is more 
effective than glimepiride in improving the quantitative and qualitative characteristics of lipoproetins 
in type 2 diabetic patients. Moreover it is effective in reducing the glyco-oxidation processes in terms 
of AGE formation. 
Pioglitazone has been demonstrated positive CV outcomes in the long-term treatment of patients with 
DM2 (PROACTIVE) (42), as recently confirmed for cerebrovascular events even in patients without 
diabetes (52).  
As already discusses, treatment with pioglitazone has demonstrated positive effects on the lipid 
profiles and oxidative stress of patients with DM2, irrespective of their glycemic control (53). 
Furthermore, treatment with pioglitazone results in a down-regulation of the AGE-RAGE system in 
patients with type 2 diabetes, probably due to the activation of antioxidant enzymes (especially 
glutathione peroxidase) as a consequence of  PPAR-γ modulation (44). All these effects could explain 
the results of PROACTIVE and IRIS studies. 
The results of our study are in line with data of the literature. We confirmed that a 5-years treatment 
with pioglitazone increases HDL levels and tends to decrease TG levels. Insulin resistance has a key 
role in the pathogenesis of diabetic dyslipidemia (high TG levels, low HDL levels), as previous 
described. Pioglitazone increase in insulin sensitivity of the liver, skeletal muscle, adipose tissue (39) 
so the quantitative effects on lipoprotieins demonstrated in our study are certainly partly due to the 
insulin-sensitizing effect of the drug. 
It is to underline that patients of our study were free from cardiovascular events at baseline while in the 
PROACTIVE and IRIS studies patients had cardiovascular events at baseline. In addition in our study 
we had 5 years of treatment while all other studies had a shorter period of treatment. So we 
demonstrated that this 5-years treatment has positive quantitative effects of lipid profile in patients 
without a history of cardiovascular disease, a low-risk population. 
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On the other hand our results showed that 5-years treatment with glimepiride significantly decrease the 
HDL levels. This data could partly explain the negative effect on the cardiovascular risk of the patient 
with type 2 diabetes treated with sulphonylureas.  
A recent published meta-analysis examined 59 randomized controlled trials to define the effect of 
sulfonylurea treatment on diabetic dyslipidemia and the results suggest that sulfonylureas increase 
significantly TG levels, while decrease the HDL levels (54). 
In our study a 5-year treatment with pioglitazone had also qualitative effect on lipoproteins, in 
particular it reduces oxLDL levels while treatment with glimepiride increases their level with a 
significant difference between the two treatments. These data confirm the anti-oxidant effect of 
pioglitazone. PPARγ-agonists reduce, in a dose-dependent manner, the expression of lectin-type 
oxidized LDL receptor 1 (LOX1) (55). LOX1 is the main receptor of oxidized LDL and it is expressed 
on endothelial cells, macrophages and vascular smooth muscle cells. The oxLDL-LOX1 binding 
activates an intracellular signaling pathway that leads to the activation of NFKB and therefore to the 
production of proinflammatory cytokines and ROS, thus favoring the progression of the atherosclerotic 
process (56), as for the AGE-RAGE binding. So pioglitazone seems to reduce the oxidation of LDL 
and also to reduce the expression of the receptor for oxLDL: these effects could contain the 
atherosclerotic process and reduce the cardiovascular events. 
The reduction of oxLDL obtained with pioglitazone in our study is slight but since LDL have a shorter 
half-life and a faster turnover, oxLDL may be a less reliable marker of long-term oxidative stress in 
patients with type 2 diabetes. 
In our study we observed another important effect of piogliazone: the significant reduction of glycation 
processes, in terms of AGE levels that confirmed data available in literature. It is to underline that the 
data available in literature are obtained with studies in vitro. To our knowledge this is the first data 
obtained in vivo in type 2 diabetic patients.  
We found that the reduction of AGE levels obtained with pioglitazone was independent from the 
reduction of HbA1c levels and so it appears unrelated to the degree of glycemic control.  
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This finding is in agreement with previous observations that have shown no correlation between glyco-
oxidation products and the degree of glycemic control (57) and suggest a direct inhibitory effect of 
pioglitazone on AGE formation. In reducing the cardiovascular risk of pioglitazone, we can add the 
possible reduction of glico-oxidation processes.  
Surprisingly in our study we obtained a significant reduction of AGE levels also in patients treated 
with glimepiride. Recently Nakamura et al have demonstrated that a 24 weeks treatment with 
glimepiride reduced the toxic AGE levels in type 2 diabetic patients. (58) However there are no 
evidence of a direct effect of sulphonylureas on AGE-RAGE system.  
We hypothesized that the reduction of AGE levels obtained with glimepiride is partly due to the 
significant increase of statin use in patients from the baseline to the end of the study. In fact the results 
of the  stepwise forward multivariate regression analysis with ΔAGE as the independent variable, 
showed a slight correlation between ΔAGE and use of statin, that failed to reach statistical significance 
probably because of the small sample size.  
It has been demonstrated that after 12 months of treatment with cerivastatin the levels of AGEs are 
reduced by 21% compared to placebo in patients with type 2 diabetes (59).  
Moreover a 4-months treatment with simvastatin reduces the AGE levels and the expression of RAGE 
in atherosclerotic plaques of diabetic patients with carotid stenosis (60).   
This study has some limitations. First, the sample size is too small to draw definitive conclusions on 
the effect of the two treatments in patients with type 2 diabetes. Second, to better analyze the long-
term effect of pioglitazone and glimpeiride on glyco-oxidation processes we have to study the whole 
AGE-RAGE system (RAGE, esRAGE, sRAGE). 
On the other hand, this was the first study to examine the effect of pioglitazone, as compared with a 
sulfonylurea, on LDL oxidation and glyco-oxidation in patients with DM2 
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CONCLUSIONS 
The present study confirms and extends the evidence of a positive effect of pioglitazone on the 
qualitative and qualitative features of lipid profile. A 5-years of treatment with pioglitazone in addition 
to metformin reduces oxidation of LDL (qualitative effect) and increase HDL levels (quantitative 
effect). In addition it has an effect on glyco-oxidation processes leading to a reduction of AGE levels 
independently from the degree of glycemic control. 
The inhibition of glyco-oxidative processes is one of the mechanisms that may explain the drug ability 
to prevent cardiovascular events. 
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